abo2203
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2024 (NCT06747156)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E activator
- B-lymphocyte antigen CD19BINDING AGENT
CD19 binding agent
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07072169 | Phase 1 | May 26, 2025 | Jiao Tong University |
| NCT06747156 | Early Phase 1 (Phase 1) | Dec 31, 2024 | Jiao Tong University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiao Tong University | Academic/Hospital | 2 | 2 | 1 | 2024 |
1 organizations
Page 1 / 1